Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-09-04
2007-09-04
Schnizer, Richard (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S001000
Reexamination Certificate
active
10224173
ABSTRACT:
The present invention provides methods and compositions for delivering a therapeutic agent across a membrane that has limited permeability for the therapeutic agent. The method includes delivering the therapeutic agent to the membrane in a composition which includes a sulphated chitinous polymer as a primary carrier.
REFERENCES:
patent: 4141973 (1979-02-01), Balazs
patent: 4424346 (1984-01-01), Hall et al.
patent: 4570629 (1986-02-01), Widra
patent: 4619995 (1986-10-01), Hayes
patent: 4659700 (1987-04-01), Jackson
patent: 4819617 (1989-04-01), Goldberg et al.
patent: 4868113 (1989-09-01), Jaye et al.
patent: 4886787 (1989-12-01), de Belder et al.
patent: RE33375 (1990-10-01), Luck et al.
patent: 4978332 (1990-12-01), Luck et al.
patent: 5023090 (1991-06-01), Levin
patent: 5080893 (1992-01-01), Goldberg et al.
patent: 5093319 (1992-03-01), Higham et al.
patent: 5140016 (1992-08-01), Goldberg et al.
patent: 5234915 (1993-08-01), Mathur et al.
patent: 5411988 (1995-05-01), Bockow et al.
patent: 5412084 (1995-05-01), Elson et al.
patent: 5460939 (1995-10-01), Hansbrough et al.
patent: 5462990 (1995-10-01), Hubbell et al.
patent: 5470829 (1995-11-01), Prisell et al.
patent: 5474765 (1995-12-01), Thorpe
patent: 5510102 (1996-04-01), Cochrum
patent: 5679658 (1997-10-01), Elson
patent: 2003/0219479 (2003-11-01), Chen et al.
patent: 312 208 (1989-04-01), None
patent: 368 253 (1990-05-01), None
patent: 637 450 (1995-02-01), None
patent: 650 999 (1995-05-01), None
patent: 665 022 (1995-08-01), None
patent: 1095650 (2001-05-01), None
patent: WO89/05646 (1989-06-01), None
patent: WO93/13137 (1993-07-01), None
patent: WO96/13282 (1996-05-01), None
patent: WO96/13284 (1996-05-01), None
Tokura et al (J.M.S. Pure Appl. Chem. A31(11): 1701-1718, 1994).
Kratz et al (Scand. J. Plastic Recon. Surg. Hand Surg. 31(2): 119-123, 1997).
Holme et al (Carbohydrate Res. 302:7-12, 1997).
van der Lubben et al (Eur. J. Pharm. Sci. 14 : 201-207, 2001).
Natsume et al (International journal of pharmaceutics, (Aug. 5, 1999) 185 (1) 1-12).
Thanou et al (Pharm. Res. 17(1): 27-31, 2000).
Brayden, D. et al. “Heparin absorption across the intestine: Effects of sodiumN-[8-(2-hydroxybenzoyl)amino]caprylate in rat in situ intestinal instillations and in caco-2 monolayers,”Pharmaceutical research14(12):1772-1779 (1997).
Dodane, V. et al. “Pharmaceutical applications of chitosan,”Pharm. Sci. Techn. Today1998;1:246-253.
Dodane, V. et al. “Effect of chitosan on epithelial permeability and structure,”Int. J. Pharm.May 10, 1999;182(1):21-32.
Hirano, S. et al. “Effect of sulfated derivatives of chitosan on some blood coagulant factors,”Carbohydrate Research137:205-215 (1985).
Illum, L. “Chitosan and its use as a pharmaceutical excipient,”Pharm. Res.Sep. 1998;15(9):1326-31.
Illum, L. et al. “Chitosan as a novel nasal delivery system for peptide drugs,”Pharm. Res.Aug. 1994;11(8):1186-9.
Leone-Bay, A. et al. “Synthesis and evaluation of compounds that facilitate the gastrointestinal absorption of heparin,”J. Med. Chem.41:1163-1171 (1998).
Muzzarelli, R.A.A. et al. “SulfatedN-(carboxymethyl)chitosans: novel blood anticoagulants,”Carbohydrate Res.126(2):225-231 (1984).
Thanou, M. et al. “Intestinal absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo,”J. Pharm. Sci.Jul. 2000;89(7):951-7.
Thanou, M. et al. “N-trimethylated chitosan chloride (TMC) improves the intestinal permeation of the peptide drug buserelin in vitro (Caco-2 cells) and in vivo (rats),”Pharm. Res.Jan. 2000;17(1):27-31.
Thanou, M. et al. “Effect of degree of quaternization of N-trimethyl chitosan chloride for enhanced transport of hydrophillic compounds across intestinal caco-2 cell monolayers,”J. Control Release.Feb. 14, 2000;64(1-3):15-25.
Thanou, M. et al. “Effect of N-trimethyl chitosan chloride, a novel absorption enhancer, on caco-2 intestinal epithelia and the ciliary beat frequency of chicken embryo trachea,”Int. J. Pharm.Aug. 5, 1999;185(1):73-82.
Thanou, M. “Mono-N-carboxymethyl chitosan (MCC)” Thesis, chapter 9, pp. 138-152, no date.
Tokura, S. et al. “Selective sulfation of chitin derivatives for biomedical functions,”J.M.S. Pure Appl. Chem.A31(11):1701-1718 (1994).
Whistler, R.L. et al. “Anticoagulant activity of oxidized andN- and O-sulfated chitosan,”Arch. Biochem. Biophys.142:106-110 (1971).
Elson Clive
Kydonieus Agis
Thanou Maya
Chitogenics, Inc.
Edwards Angell Palmer and Dodge
Loren Ralph
Schnizer Richard
LandOfFree
Methods of drug delivery using sulphated chitinous polymers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of drug delivery using sulphated chitinous polymers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of drug delivery using sulphated chitinous polymers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3796435